AXIM BIOTECHNOLOGIES, INC.: 10-Q filed 2013-08-14

Name: AXIM BIOTECHNOLOGIES, INC.: 10-Q filed 2013-08-14
Creator: AXIM BIOTECHNOLOGIES, INC.

What AXIM BIOTECHNOLOGIES, INC. reported in its quarterly report filed 2013-08-14 (fiscal Q2 2013): 17 published measures, 47 facts as tagged in accession 0001514955-13-000021.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-08-14
Fiscal period: fiscal Q2 2013
Accession: 0001514955-13-000021 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AXIM BIOTECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-06-30	96,341	USD
At 2012-12-31	132,824	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2013-06-30	-40,309	USD
At 2012-12-31	-4,698	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-06-30	145	USD
At 2012-12-31	19,128	USD
At 2012-06-30	1,607	USD
At 2011-12-31	23,138	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	-29,794	USD	91
2013-01-01 to 2013-06-30	-35,611	USD	181
2010-11-18 to 2013-06-30	-55,409	USD	956
2012-04-01 to 2012-06-30	-4,408	USD	91
2012-01-01 to 2012-06-30	-9,084	USD	182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	-24,983	USD	181
2010-11-18 to 2013-06-30	160	USD	956
2012-01-01 to 2012-06-30	3,959	USD	182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	10,833	USD	91
2013-01-01 to 2013-06-30	21,667	USD	181
2010-11-18 to 2013-06-30	74,999	USD	956
2012-04-01 to 2012-06-30	10,833	USD	91
2012-01-01 to 2012-06-30	21,667	USD	182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	6,000	USD	181
2010-11-18 to 2013-06-30	99,985	USD	956
2012-01-01 to 2012-06-30	24,510	USD	182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2010-11-18 to 2013-06-30	-100,000	USD	956
2012-01-01 to 2012-06-30	-50,000	USD	182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2013-06-30	-55,409	USD
At 2012-12-31	-19,798	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-06-30	7,645	USD
At 2012-12-31	39,128	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-06-30	136,650	USD
At 2012-12-31	137,522	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2013-06-30	88,696	USD
At 2012-12-31	93,696	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-06-30	33,000,000	shares
At 2012-12-31	33,000,000	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-06-30	11,700	USD
At 2012-12-31	11,700	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-04-01 to 2013-06-30	40,627	USD	91
2013-01-01 to 2013-06-30	57,278	USD	181
2010-11-18 to 2013-06-30	130,408	USD	956
2012-04-01 to 2012-06-30	15,241	USD	91
2012-01-01 to 2012-06-30	30,751	USD	182

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2013-01-01 to 2013-06-30	5,000	USD	181
2010-11-18 to 2013-06-30	11,304	USD	956
2012-01-01 to 2012-06-30	2,500	USD	182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2010-11-18 to 2013-06-30	13,000	USD	956

Inspect the source

Entity: AXIM BIOTECHNOLOGIES, INC. / CIK 0001514946
Captured: 2026-09-20T09:13:30.666Z
SEC response SHA-256: 5755093e2dfb1c20119737eacb251a5ef040e09cdc537c89d6edf9272249749e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514946.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))